102 related articles for article (PubMed ID: 14670624)
41. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
[TBL] [Abstract][Full Text] [Related]
42. The impact of tumour angiogenesis, p53 overexpression and proliferative activity (MIB-1) on survival in squamous cervical carcinoma.
Avall-Lundqvist EH; Silfverswärd C; Aspenblad U; Nilsson BR; Auer GU
Eur J Cancer; 1997 Oct; 33(11):1799-804. PubMed ID: 9470836
[TBL] [Abstract][Full Text] [Related]
43. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas.
van der Zee AG; Hollema H; Suurmeijer AJ; Krans M; Sluiter WJ; Willemse PH; Aalders JG; de Vries EG
J Clin Oncol; 1995 Jan; 13(1):70-8. PubMed ID: 7799045
[TBL] [Abstract][Full Text] [Related]
44. Normalization of EGFR mRNA levels following restoration of wild-type p53 in a head and neck squamous cell carcinoma cell line.
Grandis JR; Zeng Q; Drenning SD; Tweardy DJ
Int J Oncol; 1998 Aug; 13(2):375-8. PubMed ID: 9664135
[TBL] [Abstract][Full Text] [Related]
45. Prognostic evaluation in supratentorial astrocytic tumors using p53, epidermal growth factor receptor, c-erbB-2 immunostaining.
Hwang SL; Hong YR; Chai CY; Lin HJ; Howng SL
Kaohsiung J Med Sci; 1998 Oct; 14(10):607-15. PubMed ID: 9819502
[TBL] [Abstract][Full Text] [Related]
46. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
47. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.
Turner BC; Gumbs AA; Carbone CJ; Carter D; Glazer PM; Haffty BG
Cancer; 2000 Mar; 88(5):1091-8. PubMed ID: 10699900
[TBL] [Abstract][Full Text] [Related]
48. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy.
Hitt R; Ciruelos E; Amador ML; Benito A; Sanchez JJ; Ballestin C; Cortes-Funes H
Eur J Cancer; 2005 Feb; 41(3):453-60. PubMed ID: 15691646
[TBL] [Abstract][Full Text] [Related]
49. Hypoxia related growth factors and p53 in preoperative sera from patients with colorectal cancer--evaluation of the prognostic significance of these agents.
Sulkowski S; Wincewicz A; Zalewski B; Famulski W; Lotowska JM; Koda M; Sobaniec-Lotowska ME; Mysliwiec M; Baltaziak M; Pawlak K; Sulkowska M
Clin Chem Lab Med; 2009; 47(11):1439-45. PubMed ID: 19817649
[TBL] [Abstract][Full Text] [Related]
50. Serum evaluation of P53 protein in patients with gynaecological cancer.
Barbati A; Mariani L; Porpora MG; Anceschi M; Collini P; Lauro V; Cosmi EV
Anticancer Res; 2000; 20(2A):1033-5. PubMed ID: 10810393
[TBL] [Abstract][Full Text] [Related]
51. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
52. Correlation of p53 and Ki-67 (MIB-1) expressions with clinicopathological features and prognosis of early stage cervical squamous cell carcinomas.
Hanprasertpong J; Tungsinmunkong K; Chichareon S; Wootipoom V; Geater A; Buhachat R; Boonyapipat S
J Obstet Gynaecol Res; 2010 Jun; 36(3):572-80. PubMed ID: 20598040
[TBL] [Abstract][Full Text] [Related]
53. Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma.
Abendstein B; Marth C; Müller-Holzner E; Widschwendter M; Daxenbichler G; Zeimet AG
Cancer; 2000 Mar; 88(6):1432-7. PubMed ID: 10717627
[TBL] [Abstract][Full Text] [Related]
54. Prognostic value of p53 expression in stage IB1 cervical carcinoma.
Chen HY; Hsu CT; Lin WC; Tsai HD; Chang WC
Gynecol Obstet Invest; 2000; 49(4):266-71. PubMed ID: 10828711
[TBL] [Abstract][Full Text] [Related]
55. Expression of p27 and p53 in cervical squamous cell carcinoma patients treated with radiotherapy alone: radiotherapeutic effect and prognosis.
Oka K; Suzuki Y; Nakano T
Cancer; 2000 Jun; 88(12):2766-73. PubMed ID: 10870059
[TBL] [Abstract][Full Text] [Related]
56. Nuclear Y-box-binding protein-1 is a poor prognostic marker and related to epidermal growth factor receptor in uterine cervical cancer.
Nishio S; Ushijima K; Yamaguchi T; Sasajima Y; Tsuda H; Kasamatsu T; Kage M; Ono M; Kuwano M; Kamura T
Gynecol Oncol; 2014 Mar; 132(3):703-8. PubMed ID: 24486603
[TBL] [Abstract][Full Text] [Related]
57. MIB-1, p53, bcl-2, and WAF-1 expression in pelvic lymph nodes and primary tumors in early stage cervical carcinomas: correlation with clinical outcome.
Graflund M; Sorbe B; Karlsson M
Int J Oncol; 2002 May; 20(5):1041-7. PubMed ID: 11956602
[TBL] [Abstract][Full Text] [Related]
58. Mutant p53 product in patients with stage III cervical cancer.
Gitsch G; Kainz C; Joura E; Breitenecker G
Anticancer Res; 1992; 12(6B):2241-2. PubMed ID: 1295470
[TBL] [Abstract][Full Text] [Related]
59. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
Gadducci A; Tana R; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182
[TBL] [Abstract][Full Text] [Related]
60. Prognostic significance of serum p53 antibodies in patients with limited-stage small cell lung cancer.
Zalcman G; Trédaniel J; Schlichtholz B; Urban T; Milleron B; Lubin R; Meignin V; Couderc LJ; Hirsch A; Soussi T
Int J Cancer; 2000 Jan; 89(1):81-6. PubMed ID: 10719735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
